Logo image of CLMT

CALUMET INC (CLMT) Stock Fundamental Analysis

NASDAQ:CLMT - Nasdaq - US1314281049 - Common Stock - Currency: USD

10.48  +0.1 (+0.96%)

After market: 10.48 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CLMT. CLMT was compared to 212 industry peers in the Oil, Gas & Consumable Fuels industry. CLMT has a bad profitability rating. Also its financial health evaluation is rather negative. CLMT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLMT had negative earnings in the past year.
In the past year CLMT has reported a negative cash flow from operations.
In the past 5 years CLMT reported 4 times negative net income.
In multiple years CLMT reported negative operating cash flow during the last 5 years.
CLMT Yearly Net Income VS EBIT VS OCF VS FCFCLMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

The Return On Assets of CLMT (-9.53%) is worse than 84.91% of its industry peers.
CLMT has a worse Return On Invested Capital (1.93%) than 72.64% of its industry peers.
CLMT had an Average Return On Invested Capital over the past 3 years of 7.03%. This is significantly below the industry average of 27.43%.
The 3 year average ROIC (7.03%) for CLMT is well above the current ROIC(1.93%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -9.53%
ROE N/A
ROIC 1.93%
ROA(3y)-4.08%
ROA(5y)-6.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.03%
ROIC(5y)N/A
CLMT Yearly ROA, ROE, ROICCLMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

CLMT's Operating Margin of 0.89% is on the low side compared to the rest of the industry. CLMT is outperformed by 76.42% of its industry peers.
In the last couple of years the Operating Margin of CLMT has declined.
With a Gross Margin value of 5.95%, CLMT is not doing good in the industry: 76.89% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of CLMT has declined.
Industry RankSector Rank
OM 0.89%
PM (TTM) N/A
GM 5.95%
OM growth 3YN/A
OM growth 5Y-41.55%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.67%
GM growth 5Y-15.88%
CLMT Yearly Profit, Operating, Gross MarginsCLMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10

More info and screens

0

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CLMT is destroying value.
CLMT has more shares outstanding than it did 1 year ago.
CLMT has more shares outstanding than it did 5 years ago.
CLMT has a worse debt/assets ratio than last year.
CLMT Yearly Shares OutstandingCLMT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CLMT Yearly Total Debt VS Total AssetsCLMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

Based on the Altman-Z score of 1.27, we must say that CLMT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CLMT (1.27) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.27
ROIC/WACC0.19
WACC10.35%
CLMT Yearly LT Debt VS Equity VS FCFCLMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 0.89 indicates that CLMT may have some problems paying its short term obligations.
CLMT has a worse Current ratio (0.89) than 66.98% of its industry peers.
CLMT has a Quick Ratio of 0.89. This is a bad value and indicates that CLMT is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CLMT (0.40) is worse than 87.26% of its industry peers.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.4
CLMT Yearly Current Assets VS Current LiabilitesCLMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CLMT have decreased strongly by -434.18% in the last year.
Looking at the last year, CLMT shows a very strong growth in Revenue. The Revenue has grown by 24.26%.
Measured over the past years, CLMT shows a small growth in Revenue. The Revenue has been growing by 3.94% on average per year.
EPS 1Y (TTM)-434.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.34%
Revenue 1Y (TTM)24.26%
Revenue growth 3Y9.99%
Revenue growth 5Y3.94%
Sales Q2Q%-2.76%

3.2 Future

The Earnings Per Share is expected to grow by 29.17% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 7.25% on average over the next years.
EPS Next Y54.72%
EPS Next 2Y44.61%
EPS Next 3Y28.15%
EPS Next 5Y29.17%
Revenue Next Year-7.83%
Revenue Next 2Y-2.77%
Revenue Next 3Y4.82%
Revenue Next 5Y7.25%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLMT Yearly Revenue VS EstimatesCLMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B
CLMT Yearly EPS VS EstimatesCLMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLMT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLMT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLMT Price Earnings VS Forward Price EarningsCLMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CLMT indicates a slightly more expensive valuation: CLMT is more expensive than 68.87% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.39
CLMT Per share dataCLMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

CLMT's earnings are expected to grow with 28.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.61%
EPS Next 3Y28.15%

More info and screens

0

5. Dividend

5.1 Amount

CLMT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CALUMET INC

NASDAQ:CLMT (4/25/2025, 8:00:00 PM)

After market: 10.48 0 (0%)

10.48

+0.1 (+0.96%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)02-28 2025-02-28/bmo
Earnings (Next)05-09 2025-05-09
Inst Owners42.07%
Inst Owner Change0.24%
Ins Owners3.72%
Ins Owner Change1.13%
Market Cap903.48M
Analysts76.67
Price Target22.7 (116.6%)
Short Float %13%
Short Ratio6.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.67%
Min EPS beat(2)-55.7%
Max EPS beat(2)30.36%
EPS beat(4)3
Avg EPS beat(4)3.73%
Min EPS beat(4)-55.7%
Max EPS beat(4)30.36%
EPS beat(8)5
Avg EPS beat(8)167.78%
EPS beat(12)5
Avg EPS beat(12)-466.39%
EPS beat(16)7
Avg EPS beat(16)-327.85%
Revenue beat(2)2
Avg Revenue beat(2)5.98%
Min Revenue beat(2)0.99%
Max Revenue beat(2)10.98%
Revenue beat(4)4
Avg Revenue beat(4)8.67%
Min Revenue beat(4)0.99%
Max Revenue beat(4)13.26%
Revenue beat(8)7
Avg Revenue beat(8)7.46%
Revenue beat(12)11
Avg Revenue beat(12)10.63%
Revenue beat(16)15
Avg Revenue beat(16)11.56%
PT rev (1m)-13.59%
PT rev (3m)-11.88%
EPS NQ rev (1m)-47.9%
EPS NQ rev (3m)-116.33%
EPS NY rev (1m)-3067.57%
EPS NY rev (3m)-70079.6%
Revenue NQ rev (1m)10.75%
Revenue NQ rev (3m)1.17%
Revenue NY rev (1m)-4.05%
Revenue NY rev (3m)-6.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.17
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 16.39
EPS(TTM)-2.64
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-1.43
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS60.26
BVpS-8.26
TBVpS-10.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.53%
ROE N/A
ROCE 2.45%
ROIC 1.93%
ROICexc 1.97%
ROICexgc 2.21%
OM 0.89%
PM (TTM) N/A
GM 5.95%
FCFM N/A
ROA(3y)-4.08%
ROA(5y)-6.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.03%
ROIC(5y)N/A
ROICexc(3y)7.12%
ROICexc(5y)N/A
ROICexgc(3y)8.23%
ROICexgc(5y)N/A
ROCE(3y)8.9%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-44.77%
ROICexc growth 3YN/A
ROICexc growth 5Y-43.65%
OM growth 3YN/A
OM growth 5Y-41.55%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.67%
GM growth 5Y-15.88%
F-Score3
Asset Turnover1.88
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 10.57
Cap/Depr 51.48%
Cap/Sales 1.48%
Interest Coverage 0.2
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.4
Altman-Z 1.27
F-Score3
WACC10.35%
ROIC/WACC0.19
Cap/Depr(3y)260.7%
Cap/Depr(5y)180.19%
Cap/Sales(3y)6.59%
Cap/Sales(5y)4.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-434.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.34%
EPS Next Y54.72%
EPS Next 2Y44.61%
EPS Next 3Y28.15%
EPS Next 5Y29.17%
Revenue 1Y (TTM)24.26%
Revenue growth 3Y9.99%
Revenue growth 5Y3.94%
Sales Q2Q%-2.76%
Revenue Next Year-7.83%
Revenue Next 2Y-2.77%
Revenue Next 3Y4.82%
Revenue Next 5Y7.25%
EBIT growth 1Y-82.86%
EBIT growth 3YN/A
EBIT growth 5Y-39.24%
EBIT Next Year3275.99%
EBIT Next 3Y258.61%
EBIT Next 5Y146.58%
FCF growth 1Y57.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-211.41%
OCF growth 3YN/A
OCF growth 5YN/A